Periorbital edema and phototoxic rash associated with dasatinib: A case report

Dasatinib is an effective agent in the treatment of bcr-abl positive acute lymphoblastic leukemia and chronic myeloid leukemia cases. Various skin reactions may occur when tyrosine kinase inhibitors are used. The severity of side effects increases in phototoxic reactions with sunlight. In this case,...

Full description

Saved in:
Bibliographic Details
Main Authors: Bera Omer Ugurlu, Umit Yavuz Malkan
Format: Article
Language:English
Published: SAGE Publishing 2025-03-01
Series:SAGE Open Medical Case Reports
Online Access:https://doi.org/10.1177/2050313X251330969
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850206018997321728
author Bera Omer Ugurlu
Umit Yavuz Malkan
author_facet Bera Omer Ugurlu
Umit Yavuz Malkan
author_sort Bera Omer Ugurlu
collection DOAJ
description Dasatinib is an effective agent in the treatment of bcr-abl positive acute lymphoblastic leukemia and chronic myeloid leukemia cases. Various skin reactions may occur when tyrosine kinase inhibitors are used. The severity of side effects increases in phototoxic reactions with sunlight. In this case, a phototoxic rash that developed in a 78-year-old bcr-abl positive acute lymphoblastic leukemia patient is presented. This case supports that phototoxic reactions may occur with dasatinib and emphasizes that clinicians should be alert for this side effect.
format Article
id doaj-art-1b7c304f708f4d49a6f3e520c2da51c0
institution OA Journals
issn 2050-313X
language English
publishDate 2025-03-01
publisher SAGE Publishing
record_format Article
series SAGE Open Medical Case Reports
spelling doaj-art-1b7c304f708f4d49a6f3e520c2da51c02025-08-20T02:10:57ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-03-011310.1177/2050313X251330969Periorbital edema and phototoxic rash associated with dasatinib: A case reportBera Omer Ugurlu0Umit Yavuz Malkan1Division of Hematology, Department of Internal Medicine, Hacettepe University Medical Faculty, Ankara, TurkeyDivision of Hematology, Department of Internal Medicine, Hacettepe University Medical Faculty, Ankara, TurkeyDasatinib is an effective agent in the treatment of bcr-abl positive acute lymphoblastic leukemia and chronic myeloid leukemia cases. Various skin reactions may occur when tyrosine kinase inhibitors are used. The severity of side effects increases in phototoxic reactions with sunlight. In this case, a phototoxic rash that developed in a 78-year-old bcr-abl positive acute lymphoblastic leukemia patient is presented. This case supports that phototoxic reactions may occur with dasatinib and emphasizes that clinicians should be alert for this side effect.https://doi.org/10.1177/2050313X251330969
spellingShingle Bera Omer Ugurlu
Umit Yavuz Malkan
Periorbital edema and phototoxic rash associated with dasatinib: A case report
SAGE Open Medical Case Reports
title Periorbital edema and phototoxic rash associated with dasatinib: A case report
title_full Periorbital edema and phototoxic rash associated with dasatinib: A case report
title_fullStr Periorbital edema and phototoxic rash associated with dasatinib: A case report
title_full_unstemmed Periorbital edema and phototoxic rash associated with dasatinib: A case report
title_short Periorbital edema and phototoxic rash associated with dasatinib: A case report
title_sort periorbital edema and phototoxic rash associated with dasatinib a case report
url https://doi.org/10.1177/2050313X251330969
work_keys_str_mv AT beraomerugurlu periorbitaledemaandphototoxicrashassociatedwithdasatinibacasereport
AT umityavuzmalkan periorbitaledemaandphototoxicrashassociatedwithdasatinibacasereport